Figure 5.

Leukemia-associated phosphopeptide-specific immunity is lacking in CLL patients. (a) Comparative ELISpot analysis of enriched CD8+ T-cells from patients with CLL and healthy donors against 12 CLL-associated antigens reveals two distinct groupings. (b,c) Analysis of the average patient response against each phosphopeptide between the groups and healthy donors (b) reveals both Group1 (n=12) and Group2 (n=12) have suppressed phosphopeptide-immunity yet responses to mitogens are intact (c). (d,e,f) Kaplan-Meier analysis of overall survival (OS, d), progression free survival (PFS, e) and time to first treatment (TTFT, f) is reduced in Group1 patients, but not statistically significant. **P < 0.01 by Student’s t test comparing average responses for each phosphopeptide between HD and either Group 1 or Group 2.